Loading asset research
Longeveron Inc. Class A Common Stock
LGVNNasdaq · USD · StocksQuote as of · Exchange session not verified$7.15
+7.68%
Today
LGVN
Loading 1D prices…
Market cap
$23.4M
Volume
67.3K
52w high
$8.7052w low
$0.475Company profile
Longeveron Inc. Class A Common Stock
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Miami, FL, United States
Employees
38
Fiscal year end
1231
CIK
1721484
Session & valuation
Open$6.79
Previous close$6.64
Day high$7.36
Day low$6.64
30-day avg. volume366.9K
Outstanding shares—
Diluted EPS-$1.29
Latest annual period
P/E (trailing)-5.54
P/E (forward)-4.79
Price / book2.24
Beta-0.26
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| BFRIBiofrontera Inc. Common Stock | $23M | $41.7M | -25.26% | -$1.04 | +6.16% | Buy |
| COCPCocrystal Pharma Inc. Common Stock | $23.9M | $0.00 | — | -$0.78 | +0.81% | Buy |
| AKTXAkari Therapeutics plc ADS | $22M | $0.00 | — | $0.00 | +3.86% | Buy |
| UPCUniverse Pharmaceuticals Inc. Class A Ordinary Shares | $21.9M | $17.9B | -20.56% | -$8.06 | +12.37% | Unrated |
| TVRDTvardi Therapeutics Inc. Common Stock | $24.9M | $0.00 | — | -$3.26 | +1.91% | Buy |